secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0000950170-23-000239
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics reports ~$99M cash; FDA feedback supports 505(b)(2) pathway for RT-102; Phase 2 in H2 2023
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents, restricted cash equivalents and marketable securities of ~$99M as of Dec 31, 2022, subject to audit.
- FDA pre-IND feedback indicates 505(b)(2) pathway suitable for RT-102 (oral PTH analog for osteoporosis); Phase 2 trial expected H2 2023.
- Positive topline Phase 1 repeat-dose results for RT-102 announced in Dec 2022, meeting all endpoints.
- Plans to initiate three additional Phase 1 studies in 2023: RT-105 (adalimumab biosimilar), RT-110 (PTH for hypoparathyroidism), RT-111 (ustekinumab biosimilar).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023000239/0000950170-23-000239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023000239/rani-20230105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer